ABTA Recognizes Promising Future of "Outstanding" Medical Student
The American Brain Tumor Association has named Aubrey Bonhivert, second year medical student at The Ohio State University, as the recipient of the 2011 Lucien Rubenstein Award. The ABTA’s distinguished Scientific Advisory Council deemed Bonhivert, one of 15 ABTA Medical Student Summer Fellows in 2011, to have done outstanding brain tumor research. The Medical Student Summer Fellowship and Lucien Rubenstien Award are part of the ABTA’s commitment to supporting young investigators’ careers and populating the field of brain tumor research. Click here to read more.
Making Our Voice Heard in Washington
In January, the American Brain Tumor Association participated in the semiannual meeting of Regulatory Education and Action for Patients (REAP) in Washington, DC. The session brought together non-profit leaders from across the country for the purpose of discussing the challenges being faced in light of health care reform legislation, state and national budget concerns, and medication shortages. The national not-for-profit organizations in attendance were joined by representatives from Health and Human Services (HHS), the Health Resources and Services Administration (HRSA), the Food and Drug Administration (FDA), the National Association of Medicaid Directors and other agencies. The ABTA participates with such patient advocacy groups as REAP, so that as issues of importance to our constituents arise—in Washington and around the country—we are able to ensure that our voice is heard on behalf of the brain tumor community.
Help Make Breakthrough for Brain Tumors 5K a Success
We've made it easier than ever to support ABTA events with tips, tools and tactics that will help you achieve your fundraising goals. Visit our new website at www.breakthroughforbraintumors.org to register as an individual participant or a team and to receive event and fundraising information. If you have any questions, please contact one of our Event Coordinators at (800) 886-1281 or email@example.com. We look forward to you joining us Saturday, May 12 at Chicago's Montrose Harbor and supporting ABTA efforts towards breakthroughs for brain tumors.
Team Breakthrough: Closing in on the Bank of America Chicago Marathon
The Bank of America Chicago Marathon registration is officially sold out. However, you can still secure a spot in this world class event by joining the ABTA's Team Breakthrough. We have a limited number of post-close race entries. If you have already registered for the Bank of America Chicago Marathon, you can still join Team Breakthrough and raise funds to improve, extend and, ultimately, save the lives of brain tumor patients. Visit www.abtateambreakthrough.org to join us for any number of races being held across the nation.
Topics and Presenters Announced for 2012 National Patient and Family Conference
When: July 27 - 29, 2012
Where: Renaissance Chicago O'Hare Suites Hotel - 8500 West Bryn Mawr Avenue, Chicago
Topics for our 2012 National Patient and Family Conference will include understanding brain tumors; updates on research, quality of life and care giving; promising new treatments and much more. We are also offering a support group facilitator training on Friday, July 27. To learn more and sign up for registration information, click here.
Medical History Important Indicator of Risk for Meningioma
Results from the largest case-control study examining the relationship between family and personal medical history and meningioma risk suggest that individuals with immediate family members diagnosed with a meningioma at a young age are at greater risk for developing a meningioma. The findings, published in the December 2011 issue of the Journal of Neurosurgery, suggest a number of factors may be associated with meningioma risk including inherited genetic variants, immune factors, environmental exposures and hormonal factors. The study reviewed medical histories in 1124 meningioma patients and 1000 controls. Click here to read more.
Treatment of High-Grade Glioma (HGG) in Children and Adolescents
Physicians have historically relied on clinical information gathered from adult patients to determine treatment for pediatric high-grade gliomas (HGG), including glioblastoma multiforme, anaplastic astrocytoma and diffuse intrinsic pontine glioma. Increasingly, researchers are looking at crucial molecular data to identify more effective treatment options for children and adolescents with high-grade glioma. A recent study, reported in the October 2011 issue of Neuro-Oncology, reviewed records from more than 6000 pediatric glioma patients to determine the most effective chemotherapeutic regimens for the treatment of pediatric HGG. For additional information on these molecular findings and treatment options, click here.
Fatigue in Children and Adolescents Receiving Chemotherapy
Fatigue is one of the most frequent and distressing chemotherapy-related symptoms. A study appearing in the November 2011 issue of Oncology Nursing Forum suggests fatigue in young children is related to physical performance, whereas fatigue in adolescents is more complex and includes mental, emotional and physical components. A self-reported fatigue scale, along with physical performance tests (Timed Up and Down Stairs and the 6-Minute walk test), were used to measure fatigue in children (ages 6-12 years) and adolescents (13-17 years). Click here to read more.
Differing Factors Affect Outcomes in Brain Metastases
A recent study, reported in the December 2011 issue of Journal of Clinical Oncology, suggests that survival in brain metastases may be influenced not only by the primary site of the cancer (such as breast, lung, colon etc.) but also by several additional diagnosis-specific factors. Researchers created mathematical models that identified and weighted the importance of several prognostic factors considered significant within each primary disease-site. A recent review of the collected data confirmed that different factors – such as number of metastases, location of metastases, age and performance status – can influence survival, but the relevance of each factor varies markedly by disease site. Click here to read more.
Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit organization dedicated solely to funding brain tumor research. For nearly 40 years, the Chicago-based ABTA has been providing critical funding to researchers working toward breakthroughs in brain tumor diagnosis, treatment and care, and is the only national organization providing comprehensive resources that support the complex needs of brain tumor patients and caregivers.
Make a donation to the American Brain Tumor Association.
This information is provided by the American Brain Tumor Association, 8550 W. Bryn Mawr Ave., Suite 550, Chicago, Illinois, 60631. For more information on the American Brain Tumor Association, call toll-free: (800) 886-ABTA (2282), write firstname.lastname@example.org, or visit www.abta.org.
"American Brain Tumor Association" and "TrialConnect" are registered trademarks of the American Brain Tumor Association. The ABTA logo, the "Breakthrough for Brain Tumors" name and logo, and the "Team Breakthrough" name and logo are trademarks of the American Brain Tumor Association. All rights reserved.
Update Email Preferences | Forward to a Friend | Unsubscribe
©2012 American Brain Tumor Association
Save the Dates
February 25, 2012
April 14, 2012
May 19, 2012
hosting an ABTA event? Contact us at email@example.com.
Discover Community Support with ABTA Connections
ABTA's Connections Online Support Community links patients, families, friends, caregivers and health care professionals with each other for support and inspiration. The online community was created to provide a safe place to visit, join and interact with over 500 members of the brain tumor community nationally and around the world.
Find a Clinical Trial Through TrialConnectTM
The American Brain Tumor Association offers a service that links brain tumor patients with appropriate clinical trials based on tumor type and treatment history. TrialConnect, a free and confidential service administered by EmergingMed, is offered in English and Spanish. Read more.
Our Care Consultants provide brain tumor information, support and education for patients, families and health care professionals. They are available via email at firstname.lastname@example.org
or by calling our toll-free CareLine at (800) 886-ABTA (2282).